Results 81 to 90 of about 21,815 (182)

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont   +5 more
wiley   +1 more source

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

open access: yes, 2015
Alejo Rodriguez-Vida,1 Myria Galazi,1 Sarah Rudman,1 Simon Chowdhury,1 Cora N Sternberg2 1Medical Oncology Department, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2Medical Oncology Department, San Camillo and Forlanini Hospitals ...
Galazi M   +4 more
core  

Image1_Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?.jpeg

open access: yes, 2022
Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC ...
Dao-Sheng Luo (12098507)   +8 more
core   +1 more source

Real-World Outcomes of Combination Therapy With Radium-223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer

open access: yesAdvances in Urology
Radium-223 and enzalutamide have shown survival benefits in metastatic castration-resistant prostate cancer, and recent trial data suggest a potential synergy in combination.
Kenichi Hata   +17 more
doaj   +1 more source

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

open access: yesФармакоэкономика, 2019
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC).
N. A. Avxentyev   +2 more
doaj   +1 more source

Underestimation of Subserosal Invasion in Early Gastric Cancer‐Like Advanced Gastric Carcinoma With Focal Enteroblastic Differentiation: A Case Report

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Early gastric cancer (EGC)‐like advanced gastric cancer (AGC) is a rare entity that mimics superficial disease despite deep invasion. We report a case of EGC‐like AGC with focal enteroblastic differentiation in which subserosal invasion was underestimated because of its superficially appearing endoscopic features.
Akira Tomioka   +8 more
wiley   +1 more source

Table2_Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?.docx

open access: yes, 2022
Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC ...
Dao-Sheng Luo (12098507)   +8 more
core   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2699-2717, November 2026.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee   +3 more
wiley   +1 more source

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens

open access: yes, 2018
Yusuke Ito, Marianne D Sadar Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada Abstract: Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy ...
Ito Y, Sadar MD
core  

Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 41, 6 November 2026.
Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy